RegMedNet partners with Dimensions to provide members with free access to data on the latest regenerative medicine funding and grants.
RegMedNet, part of Future Science Group, and Dimensions, part of Digital Science, have partnered to expand access to data on the latest public and private grants and funding for regenerative medicine research. The partnership will provide members of RegMedNet, the trusted site that unites the diverse regenerative medicine community, exclusively free access to dynamic information on over US$6 billion of grants and funding around the world.
Freya Leask, Publisher, explains: “In a rapidly developing industry such as regenerative medicine and advanced therapies, insight into funding data could help identify industry trends, connect new collaborators and more. By providing free access to this amazing data set, we are supporting our members in achieving the mission of advancing the field of regenerative medicine, by applying the amazing research we report on every day to benefit the patients that need it.”
Dimensions collates over 150 million research documents, from clinical trials and academic articles to patents and more, in the most comprehensive collection of linked data in a single platform. By mapping the entire research lifecycle, users are able to follow research from funding through output to impact.
This partnership complements RegMedNet’s library of unbiased news, expert insights, educational webinars, infographics and more, making RegMedNet a one-stop shop for stakeholders in the regenerative medicine industry to keep up to date with the field and drive it forward.
Stephen Leicht, Digital Science’s Chief Operating Officer, says: “We are pleased to partner with RegMedNet and allow their members to get access to our funding and grants data. Dimensions’ linked publications and forward-looking grants data can be invaluable when doing research in a fast moving field such as regenerative medicine. We are happy to contribute to this meaningful endeavour as it aligns directly with Digital Science’s mission to improve information flows and create seamless connections to better serve the whole of the research community.”
Visit Dimensions on RegMedNet here>>
About Future Science Group
Founded in 2001, FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. Future Science Group’s portfolio consists of three publishing imprints, Future Science, Future Medicine, Newlands Press, as well as a content development imprint, PharmaPlatforms. In addition to this core publishing business, FSG develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.
FSG currently publishes 35 peer-reviewed journals as well as 8 knowledge networks and content hubs across a wide range of therapy area and scientific fields. Key journals include Future Oncology and Regenerative Medicine, alongside sites such as RegMedNet, Oncology Central and The Evidence Base.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.
Dimensions is a modern, innovative, linked research knowledge system that re-imagines discovery and access to research. Developed by Digital Science in collaboration with over 100 leading research organizations around the world, Dimensions brings together grants, publications, citations, alternative metrics, clinical trials, patents and datasets to deliver a platform that enables users to find and access the most relevant information faster, analyze the academic and broader outcomes of research, and gather insights to inform future strategy. Visit Dimensions’ website at https://dimensions.ai and find us on Twitter @DSDimensions.